| |
Decentralized clinical trials (DCTs) are redefining clinical research beyond the confines of traditional clinical trial sites. This recent shift presents immense promise for pediatric rare disease research – offering hope to patients and their families as they navigate the uncertainty of their diagnoses. Read our checklist to explore expert insights for the implementation of decentralized clinical trials in pediatric rare diseases.
|
|
Today’s Big NewsApr 17, 2024 |
| By Max Bayer Pfizer's 2023 cost-cutting wave swept up a specific R&D team that worked closely with academics to swiftly develop new medicines. A company spokesperson confirmed that Pfizer has closed labs associated with the Centers for Therapeutic Innovation. |
|
|
|
By Nick Paul Taylor Sage Therapeutics has set a bad PRECEDENT for dalzanemdor. The therapy failed to improve cognitive ability in a phase 2 Parkinson’s disease study, setting Sage off on the wrong foot at the start of a sequence of readouts that will define the future of the molecule. |
By Annalee Armstrong Fervent FDA watchers may note that the FDA typically warms to subsequent drugs in a class as they come in for review. But the Alzheimer’s space has never been like any other therapeutic area, so why would the regulatory process be any different? |
By Gabrielle Masson Sanofi’s global collaboration with IGM Biosciences has shrunk by half. The companies will now focus only on developing three IgM agonist antibodies for immunology and inflammation and shed three related oncology targets. |
|
Tuesday, April 23, 2024 | 2:00pm ET | 11:00am PT If you are embarking on the exciting journey of moving labs, this webinar is for you! Join us on April 23rd to learn from real-life stories the critical steps to a successful move and the common budget-draining mistakes to avoid. Register today!
|
|
By James Waldron Ultimovacs previously hinted at a dash to preserve cash following the failure of its cancer vaccine in a phase 2 trial. Now, the Norwegian biotech has revealed that 40% of staff will be jettisoned to keep the company afloat next year. |
By James Waldron Nine months after Eli Lilly’s Prevail Therapeutics reduced the biobucks value of a gene editing deal with Precision Biosciences, the Big Pharma subsidiary has walked away from the partnership entirely. |
By Max Bayer Canaan is adding more than $100 million to dole out to new biotechs, a year after closing an $850 million fund. A general partner for the firm expects to distribute the $1 billion over three years. |
By Nick Paul Taylor Connect Biopharma is uncoupling from Pfizer, returning the rights to an eczema candidate it picked up in 2012 to free up cash to advance its two lead programs. |
By Helen Floersh The FDA’s Center for Drug Evaluation and Research, or CDER, has established a new center for communication between CDER staff and stakeholders involved in clinical trials, according to an announcement published April 15. The end goal is to modernize clinical trials by making it easier for sponsors to innovate on their design. |
By Kevin Dunleavy In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. Now, two trials have shown that Eli Lilly’s weight loss product Zepbound (tirzepatide) can help patients overcome obstructive sleep apnea (OSA). |
By Conor Hale After setting up more than $30 billion in medtech M&A spending within less than two years, Johnson & Johnson CEO Joaquin Duato said that trajectory will continue as the company looks to latch on to long-term growth. |
By Helen Floersh Europe has launched the most clinical trials for cystic fibrosis treatments, while North America leads in those for acute myeloid leukemia, according to a pair of new reports from contract research organization Novotech. |
By Angus Liu After getting a fat check worth $30.5 million for joining Biogen as the CEO in late 2022, Chris Viehbacher saw his 2023 pay drop to just $4.1 million as the Big Biotech continues struggling. |
By Paige Minemyer A post from RansomHub claims to have four terabytes of data stolen from Change, according to analyst Dominic Alvieri. |
Fierce podcastsDon’t miss an episode |
| | Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join usto learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now.
|
|
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| eBookUnlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
| Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
